Schistosomiasis
is
one
of
the
most
neglected
parasitic
diseases
in
world.
The
new
tropical
road
map
2021–2030,
adopted
by
World
Health
Assembly,
set
global
goals
for
elimination
schistosomiasis.
current
treatment
options
like
praziquantel
schistosomiasis
are
limited.
This
review
on
nanoparticle-based
treatments
explores
various
upcoming
technologies.
Nanoparticle-based
and
vaccines
have
emerged
as
a
promising
approach
to
overcome
therapeutic
limitations
providing
targeted
sustained
delivery
drugs.
Using
literature
databases,
search
was
performed
using
syntax
Schistosoma,
praziquantel,
nanoparticles,
published
between
2010-
2023.
bibliometric
analysis
showed
that
there
has
been
decline
number
research
reports
clinical
trials
recent
years.
With
increased
funding
collaboration,
this
technology
can
be
used
develop
safe,
effective,
affordable
save
millions
lives.
Our
discussion
wants
raise
awareness
advocate
support
development
disease.
Discover Nano,
Journal Year:
2025,
Volume and Issue:
20(1)
Published: Jan. 30, 2025
Some
of
the
most
crucial
turning
points
in
treatment
strategies
for
some
major
infectious
diseases
including
AIDS,
malaria,
and
TB,
have
been
reached
with
introduction
antimicrobials
vaccines.
Drug
resistance
poor
effectiveness
are
key
limitations
that
need
to
be
overcome.
Conventional
liposomes
explored
as
a
delivery
system
bioactives
treat
provide
an
efficient
approach
maximize
therapeutic
outcomes,
drug
stability,
targetability,
reduce
side-effects
antimicrobials,
enhance
vaccine
performance
where
necessary.
However,
pathological
understanding
become
more
known,
advanced
liposomal
technologies
was
born
continue
having
profound
effect
on
targeted
chemotherapy
diseases.
This
review
therefore
provides
concise
incursion
into
recent
vogue
formulations
used
An
appraisal
immunological,
stimuli-responsive,
biomimetic
functionalized
other
novel
modifications
conventional
is
assimilated
sync
mutations
resistant
pathogens.
Nanomedicine,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 13
Published: March 18, 2025
Tuberculosis
(TB),
caused
by
Mycobacterium
tuberculosis
remains
a
significant
global
health
challenge
aggravated
drug-resistant
strains
and
prolonged
treatment
regimens.
Innovative
strategies
to
enhance
efficacy,
improve
patient
adherence,
reduce
adverse
effects
are
urgently
required.
We
explored
combination
therapy
using
bedaquiline
pretomanid
encapsulated
in
polymeric
nanoparticles
(pNPs).
Further,
active
targeting
was
achieved
through
mannose-decorated
(Man-pNPs)
for
macrophage-specific
delivery.
The
drug-loaded
pNPs
Man-pNPs
were
spray-dried
into
dry
powder
particles
drug
solubility
enable
local
lung
delivery
via
inhalation.
prepared
target
macrophages,
wherein
TB
bacteria
reside.
Formulations
exhibited
high
loading
excellent
aerosolization
performance
(MMAD
1-5
µm,
FPF
>
75%)
Man-pNPs.
formulation
enhanced
macrophage
receptor-mediated
endocytosis
phagocytosis,
improving
bacterial
inhibition.
demonstrated
similar
MIC
vitro
intracellular
M.tb
inhibition
compared
free
pNPs.
In
addition,
spheroid
model
developed
screening,
mimicking
granulomas'
physiological
conditions.
showed
superior
This
research
underscores
the
potential
of
therapy,
particulate-based
inhaled
delivery,
advance
efficient
patient-friendly
treatments.
Gels,
Journal Year:
2024,
Volume and Issue:
10(11), P. 719 - 719
Published: Nov. 7, 2024
Microneedle
(MN)
technology
has
emerged
as
a
promising
approach
for
delivering
therapeutic
agents
to
the
skin,
offering
significant
potential
in
treating
various
dermal
conditions.
Among
these
technologies,
hydrogel-forming
microneedles
(HFMNs)
represent
transformative
advancement
management
of
diseases
through
non-invasive
drug
delivery.
These
innovative
devices
consist
micrometer-sized
needles
made
native
or
crosslinked
hydrophilic
polymers,
capable
penetrating
stratum
corneum
without
damaging
underlying
tissues.
Upon
insertion,
HFMNs
rapidly
absorb
interstitial
fluid,
swelling
form
hydrogel
conduit
that
enables
efficient
transport
directly
into
microcirculation.
The
nature
enhances
patient
compliance
by
eliminating
pain
and
discomfort
associated
with
traditional
hypodermic
needles.
This
allows
delivery
wide
range
drugs,
including
macromolecules
biomacromolecules,
which
are
often
difficult
administer
dermally
due
their
size
polarity.
Moreover,
provide
controlled
regulated
release
profiles,
enabling
sustained
effects
while
minimizing
systemic
side
effects.
Additionally,
can
be
used
both
real-time
fluid
monitoring,
valuable
insights
disease
states
treatment
responses.
dual
functionality
positions
versatile
dermatology
tool
effectively
addressing
complications.
review
explores
use
polymeric
biomaterials
HFMN
fabrication
application
major
disorders,
such
acne,
psoriasis,
other
skin
Furthermore,
highlights
MN-based
treatments,
underscoring
reduce
improve
adherence,
supported
recent
literature.
Current Issues in Molecular Biology,
Journal Year:
2025,
Volume and Issue:
47(2), P. 99 - 99
Published: Feb. 5, 2025
Tuberculosis
(TB)
caused
by
Mycobacterium
tuberculosis
(M.tb)
remains
a
global
health
crisis,
with
over
10
million
people
affected
annually.
Despite
advancements
in
treatment,
M.tb
has
developed
mechanisms
to
evade
host
immune
responses,
complicating
efforts
eradicate
the
disease.
Two
emerging
cell
death
pathways,
ferroptosis
and
cuproptosis,
have
been
linked
TB
pathogenesis.
Ferroptosis,
an
iron-dependent
form
of
death,
is
driven
lipid
peroxidation
reactive
oxygen
species
(ROS)
accumulation.
This
process
can
limit
replication
depleting
intracellular
iron
inducing
macrophage
necrosis.
However,
excessive
may
lead
tissue
damage
aid
bacterial
dissemination.
Cuproptosis,
triggered
copper
accumulation,
disrupts
mitochondrial
metabolism,
leading
protein
aggregation
death.
exploits
both
metabolism
survive
within
macrophages,
manipulating
these
processes
resist
oxidative
stress
responses.
review
examines
roles
cuproptosis
TB,
discussing
how
manipulates
pathways
for
survival.
While
therapeutic
strategies
targeting
processes,
such
as
inducers
(Erastin,
RSL3)
inhibitors
(Ferrostatin-1)
ionophores
(Disulfiram,
Elesclomol)
chelators,
show
promise,
limited
understanding
potential
off-target
effects
significant
challenge.
Further
exploration
provide
insights
into
development
targeted
therapies
aimed
at
controlling
infection
while
minimizing
damage.
By
elucidating
complex
interactions
between
ferroptosis,
future
could
better
address
resistance
improve
clinical
outcomes.
Journal of Medicinal Chemistry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 3, 2025
The
urgent
need
for
safer
and
innovative
antitubercular
agents
remains
a
priority
the
scientific
community.
In
pursuit
of
this
goal,
we
designed
evaluated
novel
5-phenylfuran-2-carboxylic
acid
derivatives
targeting
Mycobacterium
tuberculosis
(Mtb)
salicylate
synthase
(MbtI),
key
enzyme,
absent
in
humans,
that
plays
crucial
role
Mtb
virulence.
Several
potent
MbtI
inhibitors
demonstrating
significant
activity
favorable
safety
profile
were
identified.
Structure-guided
optimization
yielded
5-(3-cyano-5-isobutoxyphenyl)furan-2-carboxylic
(1e),
which
exhibited
strong
inhibition
(IC50
=
11.2
μM)
promising
vitro
(MIC99
32
μM
against
M.
bovis
BCG).
Esters
1e
effectively
loaded
into
poly(2-methacryloyloxyethyl
phosphorylcholine)-poly(2-(diisopropylamino)ethyl
methacrylate)
(PMPC-PDPA)
polymersomes
(POs)
delivered
to
intracellular
mycobacteria,
resulting
reduced
viability.
This
study
provides
foundation
use
POs
development
future
MbtI-targeted
therapies
tuberculosis.
Microorganisms,
Journal Year:
2025,
Volume and Issue:
13(4), P. 722 - 722
Published: March 24, 2025
Multidrug-resistant
tuberculosis
(MDR-TB)
is
a
significant
public
health
challenge
globally,
exacerbated
by
the
limited
efficacy
of
existing
therapeutic
approaches,
prolonged
treatment
duration,
and
severe
side
effects.
As
drug
resistance
continues
to
emerge,
innovative
delivery
systems
strategies
are
critical
combating
this
crisis.
This
review
highlights
molecular
mechanisms
underlying
drugs
in
Mycobacterium
tuberculosis,
such
as
genetic
mutation,
efflux
pump
activity,
biofilm
formation,
contributing
persistence
difficulty
eradicating
MDR-TB.
Current
options,
including
second-line
drugs,
offer
effectiveness,
prompting
need
for
innovation
advanced
therapies
systems.
The
progression
discovery
has
resulted
approval
therapeutics,
bedaquiline
delamanid,
amongst
other
promising
candidates
under
investigation.
However,
overcoming
limitations
traditional
remains
challenge.
Nanotechnology
emerged
solution,
with
nanoparticle-based
offering
improved
bioavailability
targeted
controlled
release
delivery,
particularly
pulmonary
targeting
intracellular
macrophages.
Furthermore,
development
inhalable
formulations
potential
nanomedicines
bypass
presents
novel
approach
enhancing
efficacy.
Moreover,
adjunctive
therapies,
immune
modulation
host-directed
being
explored
improve
outcomes.
Immunotherapies,
cytokine
TB
vaccines,
complementary
use
antibiotics
Personalized
medicine
leveraging
genomic
profiling
both
pathogen
host,
promise
optimizing
regimens
minimizing
resistance.
underscores
importance
multidisciplinary
combining
discovery,
system
development,
address
complexities
treating
Continued
innovation,
global
collaboration,
diagnostics
essential
developing
practical,
accessible,
affordable
treatments
